. Author manuscript; available in PMC: 2020 Dec 1.

Published in final edited form as: J Pharmacokinet Pharmacodyn. 2019 Oct 4;46(6):565–576. doi: 10.1007/s10928-019-09657-0

Table 3.

Parameter estimates for the selected count model

Parameter	Definition	Estimate (RSE)	SIR median (95% CI)
λ	Population mean fungal count (log10 CFU/mL)	4.43 (2)	4.42 (4.20 – 4.67)
MM 1	Fractional increase in mean fungal count from the previous one	1.55 (4)	1.55 (1.36 – 1.75)
MM -1	Fractional decrease in mean fungal count from the previous one	1.14 (4)	1.14 (1.02 – 1.27)
TE	Rate of daily decrease in fungal count (day⁻¹)	0.156 (8)	0.154 (0.131 – 0.176)
K-100	Estimated multiplier for 100 mg arm of ASTRO-CM	1.41 (28)	1.42 (0.68 – 2.19)
K-200	Estimated multiplier for 200 mg arm of ASTRO-CM	1.42 (15)	1.45 (1.06 – 1.90)
K-300	Estimated multiplier for 300 mg arm of ASTRO-CM	1.34 (18)	1.35 (0.96 – 1.82)
K-400	Estimated multiplier for 400 mg arm of ASTRO-CM	1.48 (18)	1.51 (1.07 – 1.98)
BSV₁ in TE	Between subjective variability in TE for COAT (SD)	0.0744 (14)	0.0749 (0.0562 – 0.0953)
BSV₂ in TE	Between subjective variability in TE for ASTRO-CM (SD)	0.135 (13)	0.142 (0.111 – 0.175)

RSE is relative standard of error and SIR is sampling importance resampling.